FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT	OF C	HANGES	IN F	BENEFICIAL	OWNERSHIP
SIAILMENT	Oi O	IIANGEO		JENEI IOIAE	CVVIALICOIIII

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average but	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rodriguez Javier					2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI]										neck all appl Direct	or 10%		10% Ov	Owner	
(Last)	,	First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/14/2023									X Officer (give title below) Other (specify below) See Remarks					
555 LONG WHARF DRIVE, 12TH FLOOR				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									Lin	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) NEW HA	AVEN (CT	06511														filed by Mo		n One Repo	
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication														
												nction was ns of Rule					ion or writter	n plan	that is intende	ed to
		Tab	le I - Noi	n-Deriv	ative	Sec	uritie	es Ac	qu	ired,	Dis	oosed o	of, o	r Ben	eficia	lly Owne	d			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date		Code (Instr.					Benefici	es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount		(A) or (D)	Price	Transac (Instr. 3	ction(s)			(111341. 4)	
Common Stock 1			12/14	4/2023	3				M		521		A	(1)	5,	5,913		D		
		Т										sed of onverti				/ Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date (Month/Day/Year) if any (Month/Day/Year)				Date,		ransaction of Code (Instr. Derivative		vative irities ired r osed)	6. Date Exercisable at Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number or derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	s S Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	te ercisable		xpiration ate	Title		Amount or Number of Shares					
Restricted Stock Units	(1)	12/14/2023			M			521		(2)		(2)	Com	nmon	521	\$0.00	4,690)	D	

Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Remarks:

Chief Legal Officer, Senior Vice President and Corporate Secretary

/s/ Richard Steinhart, as

12/18/2023 Attorney in Fact for Javier

Rodriguez

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.